Evidence map›Paper›PMID 32079863›Full record

ArticleThe American journal of gastroenterology2020

Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients With Barrett's Esophagus.

Jon M Davison, John Goldblum, Udhayvir Singh Grewal, Kevin McGrath, Kenneth Fasanella, Christopher Deitrick, Aaron D DeWard, Emily A Bossart, Stephen L Hayward, Yi Zhang and 2 more

Open access · greenAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Guideline
  4. Article
  5. Review
  6. Review
  7. Emerging Biomarkers for Managing Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Utility of ancillary studies in the diagnosis and risk assessment of Barrett's esophagus and dysplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Review
  15. Review
  16. Article
  17. Endoscopic Management of Barrett's Esophagus.Digestive diseases and sciences · 2022
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jon M DavisonDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
John GoldblumDepartment of Pathology, and Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA.
Udhayvir Singh GrewalDepartment of Pathology, and Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA.
Kevin McGrathDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Kenneth FasanellaDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Christopher DeitrickDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Aaron D DeWardCernostics, Inc., Pittsburgh, Pennsylvania, USA.
Emily A BossartCernostics, Inc., Pittsburgh, Pennsylvania, USA.
Stephen L HaywardCernostics, Inc., Pittsburgh, Pennsylvania, USA.
Yi ZhangCernostics, Inc., Pittsburgh, Pennsylvania, USA.
Rebecca J Critchley-ThorneCernostics, Inc., Pittsburgh, Pennsylvania, USA.
Prashanthi N ThotaDepartment of Pathology, and Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA.
University of Pittsburgh · USCleveland Clinic · US

Funding

TissueCypher Testing for Risk Assessment in Barretts EsophagusR44CA192416 · NCI · CERNOSTICS, INC. · PI CRITCHLEY-THORNE, REBECCA · 2015 to 2016
$1.2M
NCI NIH HHS R44 CA192416
6 · The paper itself

Abstract

introductionA risk prediction test was previously validated to predict progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE). The aim of our study was to independently validate this test to predict the risk of progression to HGD/EAC in BE patients with nondysplastic (ND), indefinite for dysplasia and low-grade dysplasia (LGD).

methodsA single-blinded, case-control study was conducted to stratify patients with BE as low, intermediate, or high risk for progression to HGD/EAC within 5 years using a previously described risk prediction test. Patients with BE who progressed to HGD/EAC after at least 1 year (n = 58) were matched to patients undergoing surveillance without progression (n = 210, median surveillance 7 years). Baseline biopsies with subspecialist diagnoses of ND, indefinite for dysplasia, or LGD were tested in a blinded manner, and the predictive performance of the test was assessed.

resultsThis risk prediction test stratified patients with BE based on progression risk with the high-risk group at 4.7-fold increased risk for HGD/EAC compared with the low-risk group (95% confidence interval 2.5-8.8, P < 0.0001). Prevalence-adjusted positive predictive value at 5 years was 23%. The high-risk class and male sex provided predictive power that was independent of pathologic diagnosis, age, segment length, and hiatal hernia. Patients with ND BE who scored high risk progressed at a higher rate (26%) than patients with subspecialist-confirmed LGD (21.8%) at 5 years. DISCUSSION: A risk prediction test identifies patients with ND BE who are at high risk for progression to HGD/EAC and may benefit from early endoscopic therapy or increased surveillance.

Indexed as

AdenocarcinomaAgedAntigens, CDAntigens, Differentiation, MyelomonocyticBarrett EsophagusBiomarkersCase-Control StudiesCD68 MoleculeCyclin-Dependent Kinase Inhibitor p16Cyclooxygenase 2Disease ProgressionErb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsEsophagusFemaleHumansalpha-methylacyl-CoA racemaseAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersCD68 antigen, humanCD68 MoleculeCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Cyclooxygenase 2ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitKeratin-20Leukocyte Common AntigensRacemases and EpimerasesTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID32079863
PMCPMC7274882
OpenAlexW3008513725

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.